5 Marijuana Stocks Ready To Explode

The global coffee market, which is one of the most valuable commodities globally is valued at about $80 billion per year. Nonetheless, the global cannabis market is valued at about $142 billion. Cannabis is considered the largest cash crop in the U.S. and has a growth rate far larger than corn, cotton and wheat.

An exciting company that we have discovered CIIX (, Inc.) announced yesterday that it’s having a Hemp Oil Seminar on August 18th, 2018 at its flagship retail store, Chinese Wellness Center located at 227 West Valley Blvd. #208-B in San Gabriel, Ca.  CIIX has been making waves on the street for the last couple weeks. Yesterday alone CIIX shares traded up 47%.  If you haven’t discovered CIIX at this point, start doing your own due diligence immediately.  CIIX is unique considering it has zero convertible debt, and in our opinion CIIX could be one of the top Marijuana related stocks in the market come this fall.   

There are a number of reasons that lawmakers have been apprehensive about considering rescheduling or the complete federal legalization of cannabis. Of course, this last part could be under contention with the U.S. Food and Drug Administration on June 25th approving GW Pharmaceuticals (NASDAQ: GWPH) Epidiolex, the world’s first cannabis-derived drug. The fact is that cannabis is no longer considered by the majority of citizens an underground drug. It’s now a viable industry that’s making investors an absolute fortune globally.

These five Cannabis stocks are set to explode:, Inc. (OTCQB: CIIX), Canopy Growth Corporation (NYSE: CGC), Kush Bottles, Inc. (OTCQB: KSHB), Aphria Inc. (OTCQB:APHQF), Insys Therapeutics, Inc . (NASDAQ: INSY)., Inc. (OTCQB: CIIX)

Market Cap: $19.17M, current share price: $0.69, Inc. is responsible for the online and retail sales of hemp-based health products in the United States and has been building awareness for its ‘Opt Hemp‘ brand among Chinese consumers in the U.S. since its establishment in April 2017. In June 2017, the Company officially opened its first retail location known as Chinese Wellness Center and launched its website They also currently work with Medicine Man Denver on the creation of a new intellectual property and will be providing licensing and consulting services within the emerging Cannabis sector. 

Canopy Growth Corporation (NYSE: CGC)

Market Cap: $5.72B, current share price: $26.09

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.

Kush Bottles, Inc. (OTCQB: KSHB)

Market Cap: $304M, current share price: $4.56

Kush Bottles, Inc. is a dynamic sales and distribution platform that provides unique products and services for both businesses and consumers in the cannabis industry.

Aphria Inc. (OTCQB: APHQF)

Market Cap: $1.74B, current share price: $7.68

Aphria Inc., is one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

Insys Therapeutics, Inc. (NASDAQ: INSY)

Market Cap: $559.47M, current share price: $7.58

Insys Therapeutics, Inc., is a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and four thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX.  CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States